TUDASIDONE 40 MG 20 F.C.TABS

Atypical antipsychotic; precise mechanism is unknown; efficacy suggested to involve mediation of central dopamine type 2 and serotonin type 2 (5HT-2A) receptor antagonism. Indicated for schizophrenia 40 mg PO qDay initially; not to exceed 160 mg/day Indicated as monotherapy for adults with major depressive episode associated with bipolar I disorder (bipolar depression) 20 mg PO qDay initially; may increase dose if needed not to exceed 120 mg/day. Indicated as adjunctive therapy for major depressive episodes associated with bipolar I disorder with lithium or valproate 20 mg PO qDay initially; may increase dose if needed not to exceed 120 mg/day.